Dec 19, 2022
The American Society of Hematology (ASH) Annual Meeting this year presented abstracts showcasing new data from across its bispecific antibodies clinical pipeline, demonstrating the companies’ commitment to redefining care for patients with DLBCL. Recently, off-the-shelf bispecific antibodies have grow...
Read More...
Dec 19, 2022
American Society of Hematology (ASH) presented fresh abstracts from a strong portfolio and pipeline of cutting-edge treatment platforms for cancer and blood diseases, underscoring the significance of our audacious science in research. Delveinsight has provided a summary of some of the key abstracts and their result...
Read More...
Dec 09, 2022
Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American S...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper